Imaging and therapy of hSSTR2-transfected tumors using radiolabeled somatostatin analogs

The aim of this study was to introduce human somatostatin receptors subtype-2 ( hsstr2 ) gene into A549 lung carcinoma cells in order to investigate the role of these receptors, and to observe the lethal effect of 131 I-RC-160 (RC-160, vapreotide, an analog of somatostatin) on transfected cells through tumor scintigraphy. Clones overexpressing SSTR2 were selected for radioligand-receptor binding assay and assessment of 125 I-RC-160 internalization. The methylthiazolyl tetrazolium test was used to observe the lethal effect of 131 I-RC-160, Na 131 I, and RC-160 on hSSTR2-transfected A549 cells (A549-hSSTR2). Planar imaging was performed with a gamma camera equipped with pinhole collimator in nude mice bearing both A549-hSSTR2 tumors overexpressing SSTR2 and A549-pcDNA3 (pcDNA3-transfected A549 cells) tumors as control. Images were obtained at 0.5, 6, and 24 h after injection of 3.7 × 10 6 Bq 99m Tc-RC-160 via the tail vein. The inhibitory effects of 131 I-RC-160, RC-160, and Na 131 I on the tumors were recorded by measuring the tumor volumes. At the end of the study, the tumors were excised and HE staining was performed. The binding radioactivity (sum of membrane-bound and internalized radioligand) of A549-hSSTR2 cells was 18.24 ± 1.9 % of total counts added after 1 h of incubation, and was higher than that of A549-pcDNA3 cells 5.7 ± 1.4 % ( P < 0.05). The inhibition ratio of A549-hSSTR2 cells was 78.8 ± 5.9 %. Clear images of tumor lesions in nude mice were achieved at 0.5 h post injection. In the A549-hSSTR2 xenograft tumor group, the growth of the tumors treated with 131 I-RC-160 was significantly inhibited as compared to tumors in the group treated with RC-160 ( P < 0.01). This study demonstrated that it was possible to introduce hsstr2 to non-expressing tumor cell lines and treat tumors with radiolabeled somatostatin analogs.